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Abstract Transforming growth factor (TGF)-L1, a crucial
molecule in metastatic bone cancer, stimulates collagenase-3
expression in the human breast cancer cell line, MDA-
MB231. Cycloheximide inhibited this stimulation, indicating
that de novo protein synthesis was essential for this response.
We examined whether mitogen-activated protein kinase
(MAPK) and/or Smad pathways are involved in TGF-L1-stimu-
lated collagenase-3 expression in MDA-MB231 cells. Biochem-
ical blockade of extracellular regulated kinase-1/2 and p38
MAPK pathways partially abolished TGF-L1-stimulated colla-
genase-3 mRNA expression; whereas overexpression of a dom-
inant negative form of Smad3 completely blocked the TGF-L1-
response. These data indicate that TGF-L1-induced MAPK and
Smad pathways are involved in TGF-L1-stimulated collagenase-
3 expression in MDA-MB231 cells.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Matrix metalloproteinases (MMPs) are a family of secreted
or transmembrane proteinases that have been implicated in
multiple physiological and pathological processes related to
extracellular matrix (ECM) turnover, such as normal growth
and development, wound healing, angiogenesis, and joint de-
struction in arthritis [1^4]. MMPs also play an integral role in
tumor invasion that is characterized by increased motility of
epithelial cells and growth of metastasized tumor cells [5].
Recent studies have shown that collagenase-3 (MMP-13) is
overexpressed in a variety of malignant tumors. Human col-
lagenase-3 was originally identi¢ed in human breast carcino-
ma cells [6] and is homologous to rat collagenase-3 [7]. Due to
the wide substrate speci¢city of collagenase-3, the expression
of collagenase-3 is very restricted and appears to be subjected
to stringent regulatory mechanisms. During tumor growth
these controls are lost and tumor cells acquire the ability to
produce this protease under stimulation by di¡erent factors,
including cytokines, growth factors, and tumor promoters.
Among them, interleukin (IL) 1K and IL-1L are potential
candidates for inducing the expression of this MMP gene in
breast carcinomas [8,9].
Transforming growth factor (TGF)-L, a multipotent cyto-
kine enriched in bone matrix, has a wide range of physiolog-
ical and pathological e¡ects [10^13]. TGF-L1, a crucial mole-
cule in bone metastatic cancer, appears to help guide
completion of the bone remodeling cycle. It could also pro-
mote breast cancer metastasis by acting directly on the tumor
cells [14] via production of parathyroid hormone (PTH)-re-
lated protein (PTHrP) that is the critical mediator of bone
destruction. The molecular mechanisms responsible for osteo-
lytic metastases are complex and involve bi-directional inter-
actions between tumor cells and bone. One of the possible
ways that TGF-L1 is involved in bone destruction is via reg-
ulation of MMP activity in metastasizing bone cancer cells. In
the present study we show TGF-L1 stimulation of collage-
nase-3 mRNA expression and secretion in the human breast
cancer cell line, MDA-MB231, and the signaling pathways
mediating this response.
2. Materials and methods
2.1. Cell culture and growth factor stimulation
MDA-MB231 cells were obtained from ATCC (American Type
Culture Collection). The cells were maintained in culture in Dulbec-
co’s modi¢ed essential medium (DMEM-F12) supplemented with 10%
fetal bovine serum (FBS) at 37‡C in a humidi¢ed atmosphere of 5%
CO2 and 95% air. Cells were treated with TGF-L1 (Invitrogen) or
control vehicle in the absence of serum. Inhibitors used in these ex-
periments included the MEK-1 inhibitor PD98059 (Calbiochem), and
the p38 mitogen-activated protein kinase (MAPK) inhibitor,
SB203580 (Calbiochem). Pretreatments with these inhibitors were
for 30 min.
2.2. Semiquantitative RT-PCR
Total RNA was prepared using the Qiagen RNeasy kit. RNA ob-
tained from control and TGF-L1-treated MDA-MB231 cells was used
for reverse transcription polymerase chain reaction (RT-PCR) by
SuperScript One Step RT-PCR kit (Invitrogen). The oligonucleotides
(sense 5P-CCTCCTGGGCCAAATTATGGAG-3P and antisense 5P-
CAGCTCCGCATCAACCTGCTG-3P) corresponding to human col-
lagenase-3 were used for speci¢c ampli¢cation of a 392 bp fragment of
collagenase-3 mRNA. The initial temperature for RT-PCR was 50‡C
(30 min) and 94‡C (2 min) and then 30 cycles of denaturation (94‡C,
30 s), annealing (55‡C, 30 s), and elongation (68‡C, 1 min). The ¢nal
extension was at 68‡C (7 min). The products were analyzed on a 2%
agarose gel.
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2.3. Northern blot analysis
Twenty Wg of total RNA per lane was electrophoresed on a 1%
agarose, 2.2 M formaldehyde gel in MOPS bu¡er (40 mM MOPS,
pH 7.0, 10 mM sodium acetate and 1 mM EDTA). RNA was trans-
ferred to Zeta-Probe GT-membrane (Bio-Rad) and hybridized in 50%
formamide, 5USSC, 10UDenhardt’s, 0.1% SDS, 0.05 M NaPO4 and
100 Wg/ml salmon sperm DNA at 42‡C. cDNA probes used for hy-
bridization were labeled either with random priming by Prime-a-Gene
kit (Promega) or by nick translation kit (Promega). Northern blots
were visualized by exposure to ¢lm and quantitated by exposure to
phosphor screens and analysis in a phosphorimager.
2.4. Quantitative RT-PCR
Total RNA was prepared using the Qiagen RNeasy kit. Reverse
transcriptase reaction was carried out using the TaqMan Reverse
Transcription reagents (Roche). PCR reactions were performed ac-
cording to the real-time PCR machine manufacturer’s instructions
(DNA Engine Opticon, MJ Research, MA, USA), which allow real-
time quantitative detection of the PCR product by measuring the
increase in SYBR green £uorescence caused by binding of SYBR
green to double-stranded DNA. The SYBR green kit for PCR reac-
tions was purchased from Perkin Elmer Applied Biosystems. Primers
for human collagenase-3 and L-actin were designed using the Primer-
Express software (Perkin Elmer Applied Biosystems).
2.5. Western blot analysis
Whole cell lysates from MDA-MB231 cells containing 50 Wg of
total protein in lysis bu¡er were electrophoresed by 12% SDS^
PAGE. The proteins were transferred electrophoretically to polyvinyl-
idene di£uoride membrane (Bio-Rad). After blocking in Tween^Tris-
bu¡ered saline (0.1% Tween 20, 138 mM NaCl, 5 mM KCl, and 25
mM Tris^HCl, pH 8.0) containing 5% (w/v) non-fat dry milk, the
membrane was exposed to primary antibody overnight at 4‡C. The
membrane was washed and exposed to horseradish peroxidase-conju-
gated goat anti-rabbit secondary antibody (diluted 1:5000). The anti-
gen^antibody complexes were detected by enhanced chemilumines-
cence (Amersham Biosciences).
2.6. Transient transfection and chloramphenicol acetyltransferase
(CAT) activity
The plasmid DNAs were transiently transfected into breast cancer
cells using Lipofectamine (Invitrogen). Brie£y, cells were plated at
4U105 cells/well in six-well plates in DMEM-F12 containing 10%
FBS. The following day, the cells were transfected with 1 Wg DNA
and 5 Wl Lipofectamine per plate in 1 ml of serum-free DMEM-F12.
After 16 h, 1 ml of DMEM-F12 containing 10% FBS was added.
After 24 h, the cells were treated with either control or TGF-L-con-
taining medium for 24 h. CAT activity was measured by reacting 50 Wl
of cell lysate in duplicate in a 100 Wl reaction volume consisting of
¢nal concentrations of 250 WM n-butyryl-coenzyme A and 23 mM
[14C]chloramphenicol (0.125 WCi/assay). Butylated chloramphenicol
was removed by pre-extraction with 200 Wl of mixed xylenes. Butyl-
ated chloramphenicol retained in the ¢nal organic layer was deter-
mined by scintillation counting. The values were normalized to pro-
tein as determined by the Bradford dye binding (Bio-Rad) method. A
standard curve using puri¢ed CAT was performed every experiment
to determine the linear range of the enzyme assay.
3. Results
3.1. TGF-L1 stimulates collagenase-3 mRNA expression in
MDA-MB231 cells and it requires de novo protein
synthesis
To study the e¡ect of TGF-L1 on expression of collagenase-
Fig. 1. TGF-L1 stimulates collagenase-3 expression in MDA-MB231 cells and it requires de novo protein synthesis. A: MDA-MB231 cells were
serum starved for 24 h and then treated with TGF-L1 (10 ng/ml) at di¡erent time periods as indicated. Sense and antisense oligos for human
collagenase-3 (CPase-3) and L-actin were used for RT-PCR. B: MDA-MB231 cells were serum starved for 24 h and then treated with control
medium or medium containing TGF-L1 (10 ng/ml) for 24 h. The collagenase-3 levels in the media were measured using an ELISA kit (Amer-
sham Pharmacia). Data represent meanSS.E.M. of three replicate plates. The statistical analysis was performed using Student’s t-test and
Prism 3.0. aSigni¢cant di¡erence compared with control (P6 0.001). C: MDA-MB231 cells were serum starved for 24 h and then treated with
control medium or medium containing TGF-L1 (10 ng/ml) for 24 h in the presence or absence of cycloheximide (30 Wg/ml, added 1 h before
TGF-L1 treatment). Total RNA was subjected to Northern blot analysis and probed with labeled human collagenase-3 or L-actin cDNAs.
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3 in human breast cancer, MDA-MB231 cells were treated
with TGF-L1 either at di¡erent concentrations for 24 h or
for di¡erent time periods with 10 ng/ml. Total cellular
RNAs were puri¢ed and analyzed by semi-quantitative RT-
PCR. TGF-L1 maximally stimulated collagenase-3 RNA ex-
pression at 10 ng/ml concentration in MDA-MB231 cells
(data not shown) and requires 24 h for this e¡ect (Fig. 1A).
The identity of collagenase-3 (392 bp) and L-actin (661 bp)
PCR products was con¢rmed by transferring PCR products
to ¢lters and hybridizing to labeled human collagenase-3 and
L-actin cDNA probes, respectively.
An ELISA was then performed using an antibody to hu-
man collagenase-3 con¢rming increased secretion of collage-
nase-3 into the medium from TGF-L1-treated MDA-MB231
cells (Fig. 1B). To determine if the TGF-L1-mediated increase
in collagenase-3 mRNA is a primary response, we used the
protein synthesis inhibitor cycloheximide. As shown in Fig.
1C, cycloheximide inhibited TGF-L1 stimulation of collage-
nase-3 mRNA, indicating that de novo protein synthesis is
required for this response.
3.2. Activation of ERK1/2 and p38 MAPKs in MDA-MB231
cells by TGF-L1
Although TGF-L signaling is usually by the Smad pathway
in most of the cells studied, some of the biological actions of
TGF-L are also mediated by activation of MAPK signaling
pathways. To study the role of MAPK (extracellular signal-
regulated kinase (ERK) 1/2, p38, and JNK) pathways in the
regulation of collagenase-3 expression in MDA-MB231 cells,
we ¢rst determined the activation of these MAPKs by West-
ern blot analysis of cellular proteins at various time points (0,
15, 60, 120, and 240 min) after exposure to TGF-L1 using
antibodies against the active, phosphorylated forms of these
MAPKs (Cell Signaling Technology). The levels of activated
MAPKs (p-ERK1/2, p-p38, and p-JNK) were quantitated by
scanning densitometry and corrected for the levels of total
MAPKs (ERK1/2, p38, and JNK) in the same samples. As
shown in Fig. 2A, TGF-L1 increased the phosphorylation of
ERK1/2 (1.7-fold) at 15 min of stimulation and this reached a
maximum at 60 min (2.6-fold). p38 MAPK phosphorylation
was increased to a 7.8-fold stimulation at 60 min of TGF-L1
treatment and declined thereafter (Fig. 2B). In contrast to the
ERK1/2 and p38 MAPKs, there was no phosphorylation of
JNK upon TGF-L1 treatment (Fig. 2C).
3.3. Inhibition of TGF-L1-stimulated collagenase-3 mRNA
expression by ERK1/2 and p38 inhibition
To further elucidate the speci¢c roles of MAPKs in medi-
ating the stimulation of collagenase-3 expression by TGF-L1,
we used selective chemical inhibitors of these MAPKs. MDA-
MB231 cells were pretreated with PD98059 (25 WM), a speci¢c
inhibitor of ERK1/2 kinases MEK1/2, or SB203580 (25 WM),
a selective inhibitor of p38 MAPK, for 30 min and then
treated with TGF-L1 for 24 h. Total RNA was isolated and
subjected to real-time quantitative PCR. Both ERK1/2 and
p38 MAPK inhibitors blocked TGF-L1-stimulated collage-
nase-3 mRNA levels from a fold of 2.876S 0.617 to a fold
of 1.555S 0.306 and 1.603S 0.085, respectively (Fig. 3A). In
order to show the speci¢city of MAPK inhibitors, we used rat
osteoblastic cells (UMR 106-01) treated with PTH (1038 M).
Fig. 2. MAPK pathway activation by TGF-L1. MDA-MB231 cells
were incubated with TGF-L1 (10 ng/ml) for the times indicated. A:
Phosphorylation of ERK1/2 from whole cell lysates was determined
using Western blot with anti-phospho and anti-total ERK1/2 anti-
bodies. B: Phosphorylation of p38 MAPK from whole cell lysates
was determined using Western blot with anti-phospho and anti-total
p38 antibodies. C: Phosphorylation of JNK MAPK from whole cell
lysates was determined using Western blot with anti-phospho and
anti-total MAPK antibodies. Cell lysates from C6 cells stimulated
with or without anisomycin served as positive (+) and negative (3)
controls, respectively. The levels of phospho MAPKs and total
MAPKs were quantitated by scanning densitometry and the fold
stimulation was calculated over control (0 min).
Fig. 3. Inhibition of TGF-L1-stimulated collagenase-3 mRNA ex-
pression by ERK1/2 and p38 MAPK inhibition. A: MDA-MB231
cells were pretreated with dimethylsulfoxide (DMSO) or PD98059
or SB203580 for 30 min and incubated in the presence or absence
of TGF-L1 (10 ng/ml) for 24 h. Total RNA was isolated and sub-
jected to real-time quantitative RT-PCR using human collagenase-3
and L-actin primers. The relative levels of mRNAs were normalized
to L-actin and the change in the levels of collagenase-3 mRNA ex-
pression in response to TGF-L1 was calculated as fold change over
control. The data are represented as meanSS.D. (n=3) and were
analyzed by ANOVA using Prism 3.0. *Signi¢cant di¡erence com-
pared with control (DMSO) (P6 0.05). B: UMR 106-01 cells were
pretreated with DMSO or PD98059 or SB203580 for 30 min and in-
cubated in the presence or absence of PTH (1038 M) for 24 h. To-
tal RNA was isolated and subjected to real-time quantitative RT-
PCR using human collagenase-3 and L-actin primers as mentioned
above.
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Both ERK1/2 (Fig. 3B) and p38 MAPK (data not shown)
inhibitors had no e¡ect on PTH-induced collagenase-3 expres-
sion in UMR 106-01 cells.
3.4. TGF-L1-stimulated collagenase-3 promoter activity
depends on the Smad pathway
To determine the functional role of the Smad pathway for
TGF-L1-stimulated collagenase-3 expression in MDA-MB231
cells, the rat collagenase-3 promoter containing CAT as a
reporter gene [15] was transiently transfected into MDA-
MB231 cells along with a dominant-negative form of Smad3
(Smad3M) expression plasmid. The rat collagenase-3 pro-
moter is similar to the human collagenase-3 promoter and
most of the regulatory elements present in the rat and human
collagenase-3 promoters are highly conserved [15,16]. Over-
expression of the Smad mutant signi¢cantly abolished both
the basal and TGF-L1-stimulated collagenase-3 promoter ac-
tivity indicating that mutant Smad3 competes with endoge-
nous Smad3 to form a heterodimer with Smad2 and Smad4,
thus blocking translocation of the complex into the nucleus
(Fig. 4A). In order to determine the speci¢city of TGF-L
signaling that is mediated through the Smad pathway for
collagenase-3 promoter activity in MDA-MB231 cells, we
used the rat osteoblastic cells, UMR 106-01, with PTH
(1038 M) treatment. As shown in Fig. 4B, cotransfection of
Smad3M did not inhibit PTH-induced collagenase-3 promoter
activity in UMR 106-01 cells indicating that Smad-mediated
TGF-L signaling in MDA-MB231 cells is speci¢c.
4. Discussion
IL-1K and IL-1L are potential candidates for inducing the
expression of collagenase-3 in breast carcinomas [8,9]. TGF-L,
a multipotent growth factor highly enriched in bone matrix,
induces collagenase-3 expression in human ¢broblasts [9]. We
here demonstrated that treatment of human breast cancer cells
with TGF-L also stimulates collagenase-3 mRNA expression
and secretion. Collagenase-3-driven ECM proteolysis may
support cancer cell growth both biochemically, by exposing
mitogenic factors, and physically, by providing space for the
proliferating cells. Since TGF-L-stimulated collagenase-3 ex-
pression requires de novo protein synthesis and the collage-
nase-3 promoter contains an AP-1 site [15], AP-1 transacti-
vation may be required for collagenase-3 expression. AP-1
complex composition can selectively regulate gene transcrip-
tion and di¡erential expression of Fos and Jun family mem-
bers could play a role to regulate the expression of down-
stream target genes [9,17]. We previously showed that
di¡erential temporal stimulation of the AP-1 family members
may be responsible for collagenase-3 expression in osteoblas-
tic and non-osteoblastic cells [18].
Smad proteins have been shown to mediate the transcrip-
tional activation of various TGF-L-responsive genes such as
collagen [19], the tissue plasminogen activator inhibitor [20],
the JunB proto-oncogene [21], and the p21/WAF1/Cip1 cell
cycle inhibitor [22]. Smad proteins are the main cytoplasmic
signaling pathways in TGF-L1-stimulated collagenase-3 ex-
pression in osteoarthritic chondrocytes [23]. The Smad pro-
teins are central elements in the TGF-L-receptor signaling
pathway but are not the sole pathway activated by this recep-
tor complex. TGF-L family members often require the pres-
ence of parallel or synergistic pathways to the Smads to carry
out their full biological e¡ects, and diversity of the Smad-
interacting partners may contribute to signal speci¢city [24].
In gingival ¢broblasts, TGF-L1 activates both ERK1/2 and
p38 MAPK pathways but collagenase-3 expression depends
only on the activity of p38 MAPK and the presence of func-
tional AP-1 dimers [25]. The enhancement of collagenase-3
expression by TGF-L1 is also mediated by the p38 MAPK
pathway in transformed keratinocytes [26]. In the present
study, we evaluated the e¡ect of inhibiting the ERK1/2 or
the p38 MAPK pathways on TGF-L-stimulated collagenase-
3 mRNA expression in MDA-MB231 cells. Either of them did
not completely block the TGF-L-stimulated collagenase-3
mRNA expression indicating the participation of another
pathway (Smad) for this e¡ect. Overexpression of the domi-
nant-negative form of Smad3 completely blocked the TGF-L
stimulation of the collagenase-3 promoter suggesting that the
Smad pathway represents a major pathway for TGF-L in
these cells.
The interactions between MAPK and Smad pathways
downstream of the TGF-L receptor may be complex. Smad2
and Smad3 are direct substrates for phosphorylation by active
Fig. 4. TGF-L1-stimulated collagenase-3 promoter activation de-
pends on the Smad pathway. A: The wild type collagenase-3 pro-
moter construct (3148) was transiently cotransfected with pCMV-
Smad3Mutant (Smad3Mut) construct into MDA-MB231 cells and
then treated with control or TGF-L-containing medium for 24 h,
and assayed for CAT activity. The total amount of DNA used for
all transfections with or without the expression constructs was
equalized with pCMV. Data represent meanSS.D. of three experi-
ments. The data were analyzed by Student’s t-test and Prism 3.0.
*Signi¢cant di¡erence compared with control (P6 0.001). B: The
wild type collagenase-3 promoter construct was transiently cotrans-
fected with pCMV-Smad3Mutant construct into UMR 106-01 cells
and then treated with control or PTH (1038 M)-containing medium
for 24 h, and assayed for CAT activity. Data represent meanSS.D.
of three experiments.
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TGF-L type I receptor. Because a dominant-negative form of
Smad3 fully suppressed TGF-L responsiveness, activation of
the ERK and p38 MAPK pathways would result from tyro-
sine kinase receptors rather than from serine/threonine kinase
receptors (TGF-L receptor). Recently it has been shown that
TGF-L-stimulated ¢bronectin expression is mediated by epi-
dermal growth factor receptor transactivation, and subse-
quent activation of ERK and p38 MAPKs [27]. There may
be cross-talk between the MAPK and Smad pathways for
TGF-L-stimulated collagenase-3 expression in MDA-MB231
cells. For example, MAPKs phosphorylate Smad2/3 proteins
other than the SSXS motif activated by the TGF-L type I
receptor. Cross-talk between Smad, ERK1/2, and p38
MAPK pathways for TGF-L induction of the aggrecan gene
has been reported [28]. TGF-L1 stimulation of PTHrP is also
dependent on Smad and MAPK pathways [29]. Overall, our
studies demonstrate transcriptional activation of the collage-
nase-3 gene by TGF-L1 in human breast cancer cells and that
transcriptional activation is mediated by both the MAPK and
Smad pathways.
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